Other promising clinical trials in BRCA-mut pancreatic cancer include a phase II trial investigating the combination of the PARPi iraparib and the PD-1 Inhibitor dostarolimab (NCT04493060), a phase I trial investigating the platinum salt BTP-114 in several BRCA-mut or other DDR genes mutated solid tumors (NCT02950064) or a phase II trial evaluating the wee1-inhibitor adavosertib (the MATCH Screening trial, NCT02465060) (Supplementary Tables S1 and S2). This evidence concerns the gene WEE1 and pancreatic neoplasm.